GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qrons Inc (OTCPK:QRON) » Definitions » Total Liabilities

Qrons (QRON) Total Liabilities : $1.48 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Qrons Total Liabilities?

Qrons's Total Liabilities for the quarter that ended in Mar. 2024 was $1.48 Mil.

Qrons's quarterly Total Liabilities increased from Sep. 2023 ($1.43 Mil) to Dec. 2023 ($1.49 Mil) but then declined from Dec. 2023 ($1.49 Mil) to Mar. 2024 ($1.48 Mil).

Qrons's annual Total Liabilities increased from Dec. 2021 ($1.14 Mil) to Dec. 2022 ($1.28 Mil) and increased from Dec. 2022 ($1.28 Mil) to Dec. 2023 ($1.49 Mil).


Qrons Total Liabilities Historical Data

The historical data trend for Qrons's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qrons Total Liabilities Chart

Qrons Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 0.63 0.75 1.14 1.28 1.49

Qrons Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 1.32 1.43 1.49 1.48

Qrons Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Qrons's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.324+(0.08+0.085
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1.49

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=N/A--1.488
=N/A

Qrons's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.347+(0.08+0.048
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=1.48

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=0.004--1.471
=1.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qrons Total Liabilities Related Terms

Thank you for viewing the detailed overview of Qrons's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Qrons (QRON) Business Description

Traded in Other Exchanges
N/A
Address
28-10 Jackson Avenue, No. 26N, Long Island City, New York, NY, USA, 11101
Qrons Inc is a biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The firm has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM, for treating concussions and other diffused axonal injuries.
Executives
John N Bonfiglio officer: Chief Operating Officer C/O MICROLIN BIO, INC., NEW YORK NY 10022
Jonah Meer director, 10 percent owner, officer: CEO, CFO and Secretary 28-10 JACKSON AVENUE, #26N, LONG ISLAND CITY NY 11101
Ido Merfeld director, 10 percent owner, officer: President 153 HAGILBOA STREET, NIRIT L3 44805

Qrons (QRON) Headlines

From GuruFocus